Home > Publications database > Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. > print

001     127048
005     20240228140903.0
024 7 _ |a 10.1038/leu.2015.80
|2 doi
024 7 _ |a pmid:25787915
|2 pmid
024 7 _ |a 0887-6924
|2 ISSN
024 7 _ |a 1476-5551
|2 ISSN
024 7 _ |a altmetric:3813850
|2 altmetric
037 _ _ |a DKFZ-2017-03074
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Mai, E. K.
|b 0
245 _ _ |a Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
260 _ _ |a Basingstoke
|c 2015
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521622312_920
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (⩾VGPR) in 504 newly diagnosed, transplant-eligible multiple myeloma patients. VCD was found to be non-inferior to PAd with respect to ⩾VGPR rates (37.0 versus 34.3%, P=0.001). The rates of progressive disease (PD) were 0.4% (VCD) versus 4.8% (PAd; P=0.003). In the PAd arm, 11 of 12 patients with PD had either renal impairment (creatinine ⩾2 mg/dl) at diagnosis or the cytogenetic abnormality gain 1q21, whereas no PD was observed in these subgroups in the VCD arm. Leukocytopenia/neutropenia (⩾3°) occurred more frequently in the VCD arm (35.2% versus 11.3%, P<0.001). Neuropathy rates (⩾2°) were higher in the PAd group (14.9 versus 8.4%, P=0.03). Serious adverse events, both overall and those related to thromboembolic events, were higher in the PAd group (32.7 versus 24.0%, P=0.04 and 2.8 versus 0.4%, P=0.04). Stem cell collection was not impeded by VCD. VCD is as effective as PAd in terms of achieving ⩾VGPR rates with fewer PD and has a favorable toxicity profile. Therefore, VCD is preferable to PAd as induction therapy.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Boronic Acids
|2 NLM Chemicals
650 _ 7 |a Pyrazines
|2 NLM Chemicals
650 _ 7 |a Bortezomib
|0 69G8BD63PP
|2 NLM Chemicals
650 _ 7 |a Dexamethasone
|0 7S5I7G3JQL
|2 NLM Chemicals
650 _ 7 |a Doxorubicin
|0 80168379AG
|2 NLM Chemicals
650 _ 7 |a Cyclophosphamide
|0 8N3DW7272P
|2 NLM Chemicals
700 1 _ |a Bertsch, U.
|b 1
700 1 _ |a Dürig, J.
|b 2
700 1 _ |a Kunz, C.
|0 P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2
|b 3
|u dkfz
700 1 _ |a Haenel, M.
|b 4
700 1 _ |a Blau, I. W.
|b 5
700 1 _ |a Munder, M.
|b 6
700 1 _ |a Jauch, A.
|b 7
700 1 _ |a Schurich, B.
|b 8
700 1 _ |a Hielscher, T.
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 9
|u dkfz
700 1 _ |a Merz, M.
|b 10
700 1 _ |a Huegle-Doerr, B.
|b 11
700 1 _ |a Seckinger, A.
|b 12
700 1 _ |a Hose, D.
|b 13
700 1 _ |a Hillengass, J.
|b 14
700 1 _ |a Raab, M. S.
|b 15
700 1 _ |a Neben, K.
|b 16
700 1 _ |a Lindemann, H-W
|b 17
700 1 _ |a Zeis, M.
|b 18
700 1 _ |a Gerecke, C.
|b 19
700 1 _ |a Schmidt-Wolf, I. G. H.
|b 20
700 1 _ |a Weisel, K.
|b 21
700 1 _ |a Scheid, C.
|b 22
700 1 _ |a Salwender, H.
|b 23
700 1 _ |a Goldschmidt, H.
|b 24
773 _ _ |a 10.1038/leu.2015.80
|g Vol. 29, no. 8, p. 1721 - 1729
|0 PERI:(DE-600)2008023-2
|n 8
|p 1721 - 1729
|t Leukemia
|v 29
|y 2015
|x 1476-5551
909 C O |o oai:inrepo02.dkfz.de:127048
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LEUKEMIA : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b LEUKEMIA : 2015
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21